Sensitive detection of the K103N non-nucleoside reverse transcriptase inhibitor resistance mutation in treatment-naïve HIV-1 infected individuals by rolling circle amplification

Journal of Virological Methods

Volumn 161, Issue 1, 2009, Pages 128-135

  Wang, Bin ^a   Dwyer, Dominic E ^b   Chew, Choo Beng ^b   Kol, Chenda ^a   He, Zhong Ping ^c   Joshi, Hemal ^a   Steain, Megan C ^a   Cunningham, Anthony L ^a   Saksena, Nitin K ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c Clinical Laboratory Centre   (China)

Author keywords

103N; ARV treatment na ve; HIV drug resistance resistance mutations; HIV 1; Rolling circle amplification (RCA)

Indexed keywords

ANTIRETROVIRUS AGENT; ASPARAGINE; LYSINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANALYTIC METHOD; ARTICLE; CHINA; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MOLECULAR PROBE; MUTATIONAL ANALYSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; ROLLING CIRCLE AMPLIFICATION; SENSITIVITY AND SPECIFICITY;

ANTI-HIV AGENTS; CHINA; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION, MISSENSE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; OLIGONUCLEOTIDE PROBES; PREVALENCE; SENSITIVITY AND SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67650995441     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2009.06.004     Document Type: Article

References (34)

1. Bacheler L.T., Anton E.D., Kudish P., Baker D., Bunville J., Krakowski K., Bolling L., Aujay M., Wang X.V., Ellis D., Becker M.F., Lasut A.L., George H.J., Spalding D.R., Hollis G., and Abremski K. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44 (2000) 2475-2484
2. Barbour J.D., Hecht F.M., Wrin T., Liegler T.J., Ramstead C.A., Busch M.P., Segal M.R., Petropoulos C.J., and Grant R.M. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 18 (2004) 1683-1689
3. Behrens G.M. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 352 (2005) 1721-1722
4. Charpentier C., Dwyer D.E., Mammano F., Lecossier D., Clavel F., and Hance A.J. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J. Virol. 78 (2004) 4234-4247
5. Condra J.H., Holder D.J., Schleif W.A., Blahy O.M., Danovich R.M., Gabryelski L.J., Graham D.J., Laird D., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Yang T., Chodakewitz J.A., Deutsch P.J., Leavitt R.Y., Massari F.E., Mellors J.W., Squires K.E., Steigbigel R.T., Teppler H., and Emini E.A. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70 (1996) 8270-8276
6. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D.J., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Titus D., Yang T., Tepplert H., Squires K.E., Deutsch P.J., and Emini E.A. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374 (1995) 569-571
7. Deeks S.G. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26 Suppl. 1 (2001) S25-33
8. Dykes C., Fox K., Lloyd A., Chiulli M., Morse E., and Demeter L.M. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology 285 (2001) 193-203
9. Esnouf R., Ren J., Ross C., Jones Y., Stammers D., and Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 2 (1995) 303-308
10. Faruqi A.F., Hosono S., Driscoll M.D., Dean F.B., Alsmadi O., Bandaru R., Kumar G., Grimwade B., Zong Q., Sun Z., Du Y., Kingsmore S., Knott T., and Lasken R.S. High-throughput genotyping of single nucleotide polymorphisms with rolling circle amplification. BMC Genomics 2 1 (2001) 4
11. Gerry N.P., Witowski N.E., Day J., Hammer R.P., Barany G., and Barany F. Universal DNA microarray method for multiplex detection of low abundance point mutations. J. Mol. Biol. 292 (1999) 251-262
12. Grant R.M., Hecht F.M., Warmerdam M., Liu L., Liegler T., Petropoulos C.J., Hellmann N.S., Chesney M., Busch M.P., and Kahn J.O. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288 (2002) 181-188
13. Guay L.A., Musoke P., Fleming T., Bagenda D., Allen M., Nakabiito C., Sherman J., Bakaki P., Ducar C., Deseyve M., Emel L., Mirochnick M., Fowler M.G., Mofenson L., Miotti P., Dransfield K., Bray D., Mmiro F., and Jackson J.B. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354 (1999) 795-802
14. Günthard H.F., Wong J.K., Ignacio C.C., Havlir D.V., and Richman D.D. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res. Hum. Retroviruses 14 (1998) 869-876
15. Han X., Zhang M., Dai D., Wang Y., Zhang Z., Liu J., Geng W., Jiang Y., Takebe Y., and Shang H. Genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: baseline prevalence and subtype-specific difference. AIDS Res. Hum. Retroviruses 23 (2007) 357-364
16. Hardenbol P., Banér J., Jain M., Nilsson M., Namsaraev E.A., Karlin-Neumann G.A., Fakhrai-Rad H., Ronaghi M., Willis T.D., Landegren U., and Davis R.W. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat. Biotechnol. 21 (2003) 673-678
17. Larder B.A., and Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246 (1989) 1155-1158
18. Lawrence J.D., Mayers L., Hullsiek K.H., Collins G., Abrams D.I., Reisler R.B., Crane L.R., Schmetter B.S., Dionne T.J., Saldanha J.M., Jones M.C., and Baxter J.D. 064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N. Engl. J. Med. 349 (2003) 837-846
19. Li J.Y., Li H.P., Li L., Li H., Wang Z., Yang K., Bao Z.Y., Zhuang D.M., Liu S.Y., Liu Y.J., Xing H., and Shao Y.M. Prevalence and evolution of drug resistance HIV-1 variants in Henan. China Cell Res. 15 (2005) 843-849
20. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., Koup R.A., Mellors J.W., Connick E., Conway B., Kilby M., Wang L., Whitcomb J.M., Hellmann N.S., and Richman D.D. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347 (2002) 385-394
21. Lizardi P.M., Huang X., Zhu Z., Bray-Ward P., Thomas D.C., and Ward D.C. Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nat. Genet. 19 (1998) 225-232
22. Mocroft A., Vella S., Benfield T.L., Chiesi A., Miller V., Gargalianos P., d'Arminio, Monforte A., Yust I., Bruun J.N., Phillips A.N., and Lundgren J.D. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 352 (1998) 1725-1730
23. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P.J., Mo H.M., Markowitz M., Chernyavskiy T., Niu P., Lyons N., Hsu A., Granneman G.R., Ho D.D., Boucher C.A., Leonard J.M., Norbeck D.W., and Kempf D.J. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2 (1996) 760-766
24. Nilsson M., Malmgren H., Samiotaki M., Kwiatkowski M., Chowdhary B.P., and Landegren U. Padlock probes: circularizing oligonucleotides for localized DNA detection. Science 265 (1994) 2085-2088
25. Palmer S., Boltz V., Maldarelli F., Kearney M., Halvas E.K., Rock D., Falloon J., Davey Jr. R.T., Dewar R.L., Metcalf J.A., Mellors J.W., and Coffin J.M. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 20 (2006) 701-710
26. Pickering J., Bamford A., Godbole V., Briggs J., Scozzafava G., Roe P., Wheeler C., Ghouze F., and Cuss S. Integration of DNA ligation and rolling circle amplification for the homogeneous, end-point detection of single nucleotide polymorphisms. Nucleic Acids Res. 30 (2002) e60
27. Richman D.D., Morton S.C., Wrin T., Hellmann N., Berry S., Shapiro M.F., and Bozzette S.A. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 1393-1401
28. Saksena N.K., Wang B., Steain M.C., Yang R.G., and Zhang L.Q. Snapshot of HIV pathogenesis in China. Cell Res. 15 (2005) 953-961
29. Si X.F., Huang H.L., Wei M., Guan Q., Song Y.H., Ma P.F., Quan Y., Xing H., and Shao Y.M. Prevalence of drug resistance mutations among antiretroviral drug-naive HIV-1-infected patients in China. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 18 (2004) 308-311
30. Stringer E.M., Sinkala M., Stringer J.S., Mzyece E., Makuka I., Goldenberg R.L., Kwape P., Chilufya M., and Vermund S.H. Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS 17 (2003) 1377-1382
31. Tong Z., Kong F., Wang B., Zeng X., and Gilbert G.L. A practical method for subtyping of Streptococcus agalactiae serotype III, of human origin, using rolling circle amplification. J. Microbiol. Methods 70 (2007) 39-44
32. Wainberg M.A. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 34 Suppl. 1 (2003) S2-S7
33. Wang B., Potter S.J., Lin Y., Cunningham A.L., Dwyer D.E., Su Y., Ma X., Hou Y., and Saksena N.K. Rapid and sensitive detection of SARS Coronavirus (SARS-CoV) using rolling circle amplification. J. Clin. Microbiol. 43 (2005) 2339-2344
34. Zhang D.Y., Brandwein M., Hsuih T.C., and Li H. Amplification of target-specific, ligation-dependent circular probe. Gene 211 (1998) 277-285